therapeutics

MDPI

Editorial

Welcome to *Therapeutics*: A Note from the Editor-in-Chief

Nejat Düzgüneş

Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA 94103, USA; nduzgunes@pacific.edu

It is an honor to serve as the founding Editor-in-Chief of the open access journal *Therapeutics*.

The National Library of Medicine/PubMed lists close to 8 million articles related to therapeutics published since 1818, and about 1.5 million of these have been published in the last 5 years. Our aim in establishing this new journal is to provide a resource and forum for the announcement of new discoveries in many aspects of therapeutics, including pharmacogenomics, biological therapy, stem-cell therapy, traditional therapeutics, nanomedicine, nutrition, and drug therapy.

The World Health Organization has identified ischemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections as the four leading causes of death between 2000 and 2019. Clearly, the biomedical research community has to take on the challenge of developing highly effective treatments and cures for these diseases.

We hope that *Therapeutics* [1] will contribute to the discovery and development of therapies for these and many other diseases.

Conflicts of Interest: The author declares no conflicts of interest.

Reference

1. *Therapeutics* Home Page. Available online: https://www.mdpi.com/journal/therapeutics (accessed on 15 May 2024).

Short Biography of Author

Dr. Nejat Düzgüneş is currently a Professor in the Department of Biomedical Sciences at the University of the Pacific Arthur A. Dugoni School of Dentistry. He received his B.S. in Physics in 1972 at the Middle East Technical University in Ankara, Turkey, and his Ph.D. in Biophysical Sciences at the State University of New York at Buffalo in 1978. He was a National Cancer Institute National Research Service Award Post-doctoral Fellow in the laboratory of the late Prof. Demetrios Papahadjopoulos at the Cancer Research Institute at UCSF and, later, an Assistant Research Biochemist and Associate Research Biochemist. He was also appointed as an Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at the same university. He worked on the development and application of pH-sensitive liposomes; liposome-mediated therapy of *Mycobacterium avium-intracellulare* infections; and the fusion of influenza virus, HIV-1, and SIV with host cells. In 1990, he was appointed Chair of the Department of Microbiology at the University of the Pacific, and in 1995, he was appointed as a Professor. He and his team worked on the delivery of various antiviral agents, including protease inhibitors and antisense oligonucleotides, to HIV-1-infected cells, as well as gene therapy of HIV-1. His group has worked on the treatment of *Candida* infections, broadly neutralizing anti-HIV-1 antibodies, and suicide gene therapy and photodynamic therapy of oral cancer. He was the recipient of a Japan Society for the Promotion of Science Fellowship Award (1988), and the United Methodist University Teacher/Scholar Award (2015). Dr. Düzgüneş has received grants from the American Heart Association, the National Institutes of Health, including R01, U01 and SBIR grants, and the California Universitywide AIDS Research Program.

check for updates

Citation: Düzgüneş, N. Welcome to *Therapeutics*: A Note from the Editor-in-Chief. *Therapeutics* **2024**, *1*, 2–3. https://doi.org/10.3390/therapeutics1010002

Received: 13 June 2024
Accepted: 13 June 2024
Published: 18 June 2024